ood morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, and what-not has returned. You knew this would happen, yes? But no need to fret. We have assembled a menu of tidbits to help you along and invite you to join us for a cup of stimulation — vanilla macadamia nut, in our case — to cope. So dig in and have a great day. …

Teva Pharmaceuticals (TEVA) hired Lundbeck’s (LUN) Kare Schultz as its new chief executive, ending a seven-month search for a new leader to jumpstart sales, lower debt, and restore investor confidence after a controversial acquisition spree. Schultz, 56, who has been running Lundbeck and will move to Israel, faces pressure to either to maintain Teva as both a generics and specialty drug maker, split the company in two, or exit generics altogether.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.